Background
==========

Acquired resistance to carbapenems in *Enterobacteriaceae* is a major concern worldwide. This is due both to their importance as human pathogens especially within the hospital setting, and to the highly transmissible nature and propensity for rapid spread shown by these organisms. An increasingly diverse range of enzymes are being recognised as significant, including serine proteases of Ambler Class A, the Class B metallo-β-lactamases and carbapenem-hydrolysing Class D oxacillinases \[[@B1]\]. Originally found in *Shewanella* species, OXA-48-like carbapenemases have now emerged in *Enterobacteriaceae*, predominantly *Klebsiella pneumoniae*. These carbapenem hydrolysing Class D β-lactamases are unusual among carbapenemases in their weak hydrolysis of cephalosporins and resistance to inhibitors such as clavulanate, making them difficult to identify in the laboratory \[[@B2]\]. OXA-181, a variant of OXA-48, was initially reported in India but has been sporadically detected in the United Kingdom, The Netherlands, France, New Zealand, Oman and Singapore \[[@B2]-[@B7]\]. Molecular characterisation of this emerging variant remains limited.

Until recently, the vast majority of carbapenem resistance in this group of organisms was due to extended spectrum β-lactamase (ESBL) or AmpC cephalosporinase production combined with impermeability due to porin mutations \[[@B8]\]. Carbapenemase producing organisms were infrequently reported. Between October 2010 and March 2012, we screened 96 *Enterobacteriaceae* clinical isolates with MIC ≥ 2 mg/L to meropenem or imipenem for acquired carbapenemases using polymerase chain reaction (PCR). Isolates were referred for investigation from seven of eight (87.5%) hospital or community laboratories in Singapore after initial antimicrobial susceptibility testing showed non-susceptibility to carbapenems. Epidemiological data was not provided by referring laboratories. Carbapenemase genes were detected in 33 (33/96, 34.4%), including eight clinical isolates of OXA-181-producing *Klebsiella pneumoniae* from patients in three different hospitals. NDM-1 producing isolates dominated this study at 64% (21/33) whilst OXA-181 producers constituted 24.5% (8/33) of carbapenemase producing isolates thus making *bla*~OXA-181~ the second most detected carbapenemase gene after *bla*~NDM-1~\[[@B9]\]. The remaining were KPC producers (4/33) \[[@B10]\]. Here, we report the molecular characterisation of seven out of the eight of the OXA-181 producing isolates. One isolate was excluded from analysis as consent was not obtained from the referring laboratory.

Methods
=======

All isolates were confirmed as *K*. *pneumoniae* using matrix assisted laser desorption ionisation-time of flight-mass spectrometry (MALDI-ToF-MS, Bruker Daltonics GmHB, Bremen, Germany). Antimicrobial susceptibility testing was performed with VITEK-2 instrument and carbapenem MICs confirmed with Etest (bioMérieux, Marcy L'Etoile, France) with susceptibility defined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Presence of carbapenemases were screened phenotypically using disc diffusion assays with meropenem discs supplemented with boronic acid, cloxacillin or dipicolinic acid (Rosco Diagnostica A/S, Taastrup, Denmark) and the modified Hodge test \[[@B11]\].

Isolates underwent screening for transmissible β-lactamase genes including serine carbapenemases (KPC-type), metallo-β-lactamases (MBL; NDM-type, VIM-type, IMP-type), oxacillinases and extended spectrum β-lactamases (ESBL; TEM-type, SHV-type, CTX-M-type) with PCR followed by sequencing of amplicons \[[@B9],[@B10]\]. Detection of *bla*~OXA~ was based on a multiplex PCR assay developed by Woodford *et al*. \[[@B12]\] with addition of *bla*~OXA-48-like~ primers (OXA-48L 5^′^- GTGGGATGGACAGACGCG-3^′^ and OXA-48 LL 5^′^-CCACACATTATCATCAAGTTC-3^′^) using National Collection of Type Cultures (NTCT) 13442 *K*. *pneumoniae* as positive control for *bla*~OXA-48~. Plasmid mediated 16S rRNA methylase aminoglycoside resistance determinants (*arm*A, *rmt*A, *rmt*B, *rmt*C, *rmtD* and *npm*A) were also analysed by PCR.

Clonal relatedness was investigated using Multilocus sequence typing (MLST, <http://www.pasteur.fr/recherche/genopole/PF8/mlst>) and Pulsed Field Gel Electrophoresis (PFGE) of SpeI (New England Biolabs, Ipswich, MA) digested genomic DNA \[[@B13]\].

The number and size of plasmids were analysed by S1 nuclease digestion of whole genomic DNA followed by PFGE (S1-PFGE) \[[@B14]\]. In addition, smaller plasmids were extracted using the QIAprep spin miniprep kit (Qiagen GmbH, Hilden, Germany). Southern hybridisation using a digoxigenin (DIG) labelled *bla*~OXA-181~ probe (DIG DNA Labelling and Detection kit, Roche Diagnostics, Mannheim, Germany) was used to localise *bla*~OXA-181~. Transformation studies were performed with plasmid DNA extracted using QIAprep Spin Miniprep kit introduced by electroporation into *E*. *coli* DH5α cells using Gene Pulser Xcell (Bio-Rad, Hercules, CA) with transformants selected on Luria-Bertani (LB) agar supplemented with imipenem (1 mg/L). Conjugation experiments were performed between *K*. *pneumoniae* isolates and azide-resistant recipient *E*.*coli* J53 with transconjugants selected on LB agar containing sodium azide (50 mg/L) and imipenem (1 mg/L). PCR-based replicon typing was used to identify plasmid incompatibility groups \[[@B15]\]. To analyse the immediate genetic environment of the *bla*~OXA-181~ gene in our isolates, primers (IRF 5^′^-CCTAGATTCTACGTCAGTAC-3^′^ and IRR2 5^′^-CTCTCTAGTCGGACAACACC-3^′^) based on GenBank reference sequence NC_019160.1, designed to walk in from the left and right inverted long repeats (IRL) in the direction of *bla*~OXA-181~ were used.

Results and discussion
======================

As part of a surveillance program for carbapenem non-susceptible Enterobacteriaceae in Singapore, 96 isolates from seven hospitals or private laboratories were submitted for investigation. Of these, 33 clinical isolates contained carbapenemase genes as detected by PCR with eight isolates bearing *bla*~OXA-181~. Consent from referring laboratories was obtained for seven of these isolates to be subjected to molecular characterisation. The *bla*~OXA-181~ positive clinical isolates were confirmed as *Klebsiella pneumoniae* by MALDI-ToF MS. Most showed high level resistance to carbapenems, and interestingly also to cephalosporins (Table [1](#T1){ref-type="table"}), suggesting the presence of other resistance determinants in addition to *bla*~OXA-181~. Two of the seven isolates were resistant to all antimicrobial agents tested including colistin. All seven OXA-181 producers were positive by the modified Hodge test. No synergy was detected using disc diffusion assays, the usual pattern seen with oxacillinase presence.

###### 

**Characteristics of OXA-181-producing*Klebsiella pneumoniae*clinical isolates**

  **Isolate**        **Hospital**     **Specimen**      **Date of Isolation**   **ST**   **16S rRNA methylase gene**             **β-lactamases**                    **Plasmids**          **MIC** (**mg**/**L**)                                                                                         
  ----------------- -------------- ------------------- ----------------------- -------- ----------------------------- --------------------------------------- --------------------------- ------------------------ ------- ------- ------ ------- ------- ------- ------- ------- ------- ------- ------- -------
  KPO8                Hospital A    Tracheal aspirate        18/01/2011           17               *armA*                TEM-116, SHV-11, CTX-M-15, OXA-1             \~97, \~170                   A/C             \>32    \>32    \>32   \>256   \>256    64     \>256   0.125     2     0.25    \>256   \>256
  KPO9                Hospital A         Sputum               8/02/2011           17               *armA*                 TEM-1, SHV-11, CTX-M-15, OXA-1           \~9, \~150, \~170                A/C             \>32    \>32    \>32   \>256   \>256    64     \>256    16     \>256   \>256   \>256   \>256
  KPO7                Hospital A    Tracheal aspirate         9/12/2010           14               *armA*              TEM-1, SHV-1, CTX-M-15, OXA-1, OXA-9    \~1.5, \~50, \~170, \~194           A/C, F           \>32    \>32    \>32   \>256   \>256   \>256   \>256   0.25     12     \>256   \>256   \>256
  KPO26               Hospital A         Sputum              14/05/2011           14                 ND                TEM-1, SHV-1, CTX-M-15, OXA-1, OXA-9          \~1.6, \~194                   A/C             \>32    \>32    \>32   \>256   \>256   \>256   \>256    32       4     \>256   \>256    96
  KPO6916             Hospital A          Blood               2/03/2012           14               *armA*              TEM-1, SHV-1, CTX-M-15, OXA-1, OXA-9    \~1.6, \~50, \~170, \~194            A/C               8       8     \>32   \>256   \>256   \>256   \>256   0.25     16     \>256   \>256   \>256
  KPO7431             Hospital B          Urine              22/02/2012           14               *armA*              TEM-1, SHV-11, CTX-M-15, OXA-1, OXA-9   \~1.5, \~50, \~170, \~194           A/C, F             4       4     \>32   \>256   \>256   \>256   \>256   0.25      8     \>256   \>256   \>256
  KPO83               Hospital C          Urine              30/12/2011           14               *armA*              TEM-1, SHV-1, CTX-M-15, OXA-1, OXA-9              \~170                      A/C              32       8     \>32   \>256   \>256   \>256   \>256    0.5     16      32     \>256   \>256
  KPO9--T                 ―                 ―                     ―               ―                *armA*                        OXA-181, CTX-M-15                       \~170                      A/C               2      0.5    0.5      2       3       1     0.75    0.125   0.125   0.002   \>256   \>256
  KPO26 --T               ―                 ―                     ―               ―                  ND                           OXA-181, OXA-9                         \~194                      A/C               2     0.19    0.25    12       6       2       6     0.125   0.125   0.003   0.125     1
  *E*. *coli* J53         ―                 ―                     ―               ―                   ―                                  ―                                 ―                         ―              0.125   0.016   0.04     1     0.064   0.25    0.064   0.125   0.064   0.004   0.125   0.125

Legend:

MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; ETP, ertapenem; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; AZT, aztreonam; COL, colistin; TCG, tigecycline; LEV, levofloxacin; GEN, gentamicin; AMK, amikacin; KPO8, KPO9, KPO7, KPO26, KPO6916, KPO7431, KPO83 carbapenem-resistant *K*. *pneumoniae* clinical isolate; KP09-T, KP026-T, *K*. *pneumoniae* transconjugant from KP09, KP026; J53, *E*. *coli* recipient strain.

Full gene sequencing of amplicons revealed 100% identity with *bla*~OXA-181~ \[GenBank: JN205800.1\]. PCR screening and sequencing showed that all isolates also carried ESBL genes and at least one additional *bla*~OXA-type~ but none were positive for MLBs or KPC-type β-lactamases (Table [1](#T1){ref-type="table"}). *arm*A was detected in six of the seven isolates (Table [1](#T1){ref-type="table"}). MLST revealed five isolates of sequence type (ST)14 and two of ST17. Furthermore, isolates belonging to the same sequence type had identical PFGE patterns. OXA-181-producing isolates came from three different hospitals over a 15 month period, and to our knowledge patients did not have an epidemiological link to each other although full data is not accessible.

Analysis of plasmid content using miniprep kit extractions and S1-PFGE revealed the isolates contained multiple small (\~1.5kb) and large plasmids (\~50 - \~194kb) (Table [1](#T1){ref-type="table"}). Southern hybridization studies using a *bla*~OXA-181~ probe localised the gene to a large plasmid of \~170kb in six of the seven clinical isolates and to a \~194kb plasmid in isolate KPO26 (Table [1](#T1){ref-type="table"}). Transformation studies were not successful in selecting transformants; however, the method would have only extracted small plasmids. This would support localisation of *bla*~OXA-181~ to large plasmids. Previously *bla*~OXA-181~ has been described in a range of plasmid backbones ranging from a small ColE2-type plasmid of \~7.6kb in *K*. *pneumoniae* KP3 to large plasmids of 200-250kb \[[@B3],[@B16]\]. Transconjugants were obtained for only two isolates (KPO-9, KPO-26) with transfer of a large plasmid carrying *bla*~OXA-181~ demonstrated by S1-PFGE and Southern hybridization analysis (data not shown). Transconjugant KPO-26 remained susceptible to non-β-lactam antibiotics whilst for KPO-9, *armA* was co-transferred with the plasmid (Table [1](#T1){ref-type="table"}).

To further characterize the plasmids, PCR- based replicon typing was performed. IncA/C replicons were detected in all isolates including the transconjugants (Table [1](#T1){ref-type="table"}), suggesting *bla*~OXA-181~ was present on an IncA/C plasmid although Southern hybridisation analysis using IncA/C probes would be needed to confirm this. Plasmids belonging to the IncA/C incompatibility group are of interest as they carry resistance to diverse groups of antimicrobial agents and have a broad host range \[[@B17]\].

*bla*~OXA-181~ has been found as part of transposon, Tn*2013*, with upstream insertion sequence IS*Ecp1* mediating one-ended transposition of the *bla*~OXA-181~ gene \[[@B16]\]. The immediate genetic environment surrounding *bla*~OXA-181~ of our isolates was investigated. Gene mapping demonstrated presence of the IS*Ecp1* element upstream, however, no PCR products were obtained when attempting to amplify downstream sequences (*Δlys* and *Δere*). This raises the possibility that *bla*~OXA-181~ in our isolates could be present in a structure different to the previously characterized Tn*2013*\[[@B16]\].

The surveillance project from which these isolates were derived is ongoing. This project has previously identified that NDM-1 containing organisms appear to be well established in different *Enterobacteriaceae* species, often in patients without travel history within the preceding year and that KPC-2-producing *Klebsiella pneumoniae* has been introduced to Singapore probably from mainland China \[[@B9],[@B10]\]. Our work suggests that *bla*~OXA-181~ may already have established on plasmids within successful *K*. *pneumoniae* strains in Singapore. There is also the likelihood that a much wider reservoir of carbapenemase-producing *Enterobacteriaceae* already exists here given that this is a voluntary programme and only clinical isolates with obviously elevated carbapenem MICs were referred for investigation. This could be especially true for organisms carrying OXA-48-like carbapenemases which may not exhibit high level resistance to carbapenems or cephalosporins in the absence of other resistance determinants capable of conferring carbapenem non-susceptibility. A major limitation of our study is that clinical data on patients from whom the isolates were obtained is lacking. Although all isolates studied in this collection came from clinical samples, no data is available on whether these represent colonisation or true infection, nor regarding treatment and outcomes. This makes establishing the context of carbapenem resistance in *Enterobacteriaceae* in Singapore more difficult. Indeed, any data on carbapenemase-producing *Enterobacteriaceae* is very limited in South East Asia. Given the frequency of travel and economic migration through many parts of the region and the widespread resistance to other antimicrobial classes, carbapenemase production in *Enterobacteriaceae* is likely to be an under-estimated entity, made more difficult by the lack of availability for diagnostic testing in many areas.

Conclusion
==========

OXA-181 carbapenemase appears to be an emerging and probably under-recognised cause of carbapenem resistance in Enterobacteriaceae in Singapore. This preliminary data, along with the work of others \[[@B7]\], has provided the basis for establishing further coordinated clinical and molecular epidemiological research into carbapenemase-producing Enterobacteriaceae in Singapore aimed at addressing many of the gaps in our current understanding.
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